Christopher Liu
Stock Analyst at LUCID CAPITAL MARKETS
(2.98)
# 1,298
Out of 5,182 analysts
10
Total ratings
85.71%
Success rate
52.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLMD Relmada Therapeutics | Initiates: Buy | $14 | $7.03 | +99.15% | 1 | Mar 2, 2026 | |
| EXEL Exelixis | Upgrades: Outperform | $48 | $44.65 | +7.50% | 2 | Oct 21, 2025 | |
| LYEL Lyell Immunopharma | Initiates: Buy | $20 | $22.77 | -12.17% | 1 | Sep 26, 2025 | |
| ADAG Adagene | Initiates: Buy | $9 | $3.56 | +152.81% | 1 | Sep 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $10 | $2.56 | +290.63% | 1 | Jul 21, 2025 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $14.95 | +20.40% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $29.48 | -8.41% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $104.04 | -59.63% | 1 | Aug 8, 2023 |
Relmada Therapeutics
Mar 2, 2026
Initiates: Buy
Price Target: $14
Current: $7.03
Upside: +99.15%
Exelixis
Oct 21, 2025
Upgrades: Outperform
Price Target: $48
Current: $44.65
Upside: +7.50%
Lyell Immunopharma
Sep 26, 2025
Initiates: Buy
Price Target: $20
Current: $22.77
Upside: -12.17%
Adagene
Sep 18, 2025
Initiates: Buy
Price Target: $9
Current: $3.56
Upside: +152.81%
Genelux
Jul 21, 2025
Initiates: Buy
Price Target: $10
Current: $2.56
Upside: +290.63%
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $14.95
Upside: +20.40%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $29.48
Upside: -8.41%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $104.04
Upside: -59.63%